Aclaris Therapeutics (ACRS) Competitors $3.96 -0.63 (-13.73%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACRS vs. EOLS, APLT, AVDL, ZYME, SEPN, COGT, BCAX, BCYC, COLL, and PAHCShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Evolus (EOLS), Applied Therapeutics (APLT), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Septerna (SEPN), Cogent Biosciences (COGT), Bicara Therapeutics (BCAX), Bicycle Therapeutics (BCYC), Collegium Pharmaceutical (COLL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Evolus Applied Therapeutics Avadel Pharmaceuticals Zymeworks Septerna Cogent Biosciences Bicara Therapeutics Bicycle Therapeutics Collegium Pharmaceutical Phibro Animal Health Aclaris Therapeutics (NASDAQ:ACRS) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability. Is ACRS or EOLS more profitable? Evolus has a net margin of -22.33% compared to Aclaris Therapeutics' net margin of -136.65%. Aclaris Therapeutics' return on equity of -40.26% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% Evolus -22.33%-847.60%-22.15% Does the MarketBeat Community believe in ACRS or EOLS? Aclaris Therapeutics received 31 more outperform votes than Evolus when rated by MarketBeat users. However, 72.58% of users gave Evolus an outperform vote while only 66.61% of users gave Aclaris Therapeutics an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes38366.61% Underperform Votes19233.39% EvolusOutperform Votes35272.58% Underperform Votes13327.42% Which has higher earnings and valuation, ACRS or EOLS? Evolus has higher revenue and earnings than Aclaris Therapeutics. Evolus is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$31.25M9.05-$88.48M-$0.52-7.62Evolus$202.09M3.96-$61.69M-$0.91-13.88 Does the media prefer ACRS or EOLS? In the previous week, Aclaris Therapeutics had 30 more articles in the media than Evolus. MarketBeat recorded 32 mentions for Aclaris Therapeutics and 2 mentions for Evolus. Evolus' average media sentiment score of 1.32 beat Aclaris Therapeutics' score of 0.67 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 5 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of ACRS or EOLS? 98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, ACRS or EOLS? Aclaris Therapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Do analysts recommend ACRS or EOLS? Aclaris Therapeutics currently has a consensus target price of $8.80, indicating a potential upside of 122.22%. Evolus has a consensus target price of $23.00, indicating a potential upside of 82.11%. Given Aclaris Therapeutics' higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Evolus 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAclaris Therapeutics beats Evolus on 11 of the 18 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$282.86M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.21%4.07%P/E Ratio-7.6210.02126.5217.52Price / Sales9.05318.981,203.9085.12Price / CashN/A22.1633.3732.51Price / Book1.785.464.684.68Net Income-$88.48M$152.97M$118.36M$225.62M7 Day Performance62.30%-4.33%-2.46%-2.04%1 Month Performance232.77%-8.65%-4.06%0.03%1 Year Performance321.19%28.53%29.55%24.47% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics3.9469 of 5 stars$3.96-13.7%$8.80+122.2%+321.2%$282.86M$31.25M-7.6286Analyst UpgradeInsider TradeNews CoverageGap DownHigh Trading VolumeEOLSEvolus4.0221 of 5 stars$12.63+1.9%$23.00+82.1%+28.4%$799.73M$202.09M-13.88170Positive NewsAPLTApplied Therapeutics4.3431 of 5 stars$9.43+5.6%$12.50+32.6%+373.9%$1.10B$9.99M-5.8330AVDLAvadel Pharmaceuticals2.3424 of 5 stars$10.75+0.3%$24.43+127.2%-7.5%$1.03B$138.16M-13.61154Short Interest ↓ZYMEZymeworks2.8655 of 5 stars$14.55-1.5%$19.00+30.6%+74.0%$1.02B$76.01M0.00290SEPNSepternaN/A$22.50-7.0%$43.67+94.1%N/A$1.02BN/A0.00N/AAnalyst ForecastNews CoverageGap UpCOGTCogent Biosciences2.866 of 5 stars$9.08+0.2%$14.83+63.4%+20.6%$1.00BN/A0.0080Analyst RevisionBCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.00BN/A0.0032Analyst RevisionBCYCBicycle Therapeutics2.8495 of 5 stars$20.36-0.6%$40.13+97.1%+49.4%$968.12M$26.98M-6.19240Analyst RevisionCOLLCollegium Pharmaceutical3.9744 of 5 stars$30.00+0.8%$42.60+42.0%+17.2%$967.50M$566.77M12.93210PAHCPhibro Animal Health4.2227 of 5 stars$23.39-1.5%$16.50-29.5%+123.4%$961.95M$1.02B54.401,940Analyst Downgrade Related Companies and Tools Related Companies Evolus Competitors Applied Therapeutics Competitors Avadel Pharmaceuticals Competitors Zymeworks Competitors Septerna Competitors Cogent Biosciences Competitors Bicara Therapeutics Competitors Bicycle Therapeutics Competitors Collegium Pharmaceutical Competitors Phibro Animal Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACRS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRS Stock Alerts